Diffuse large B cell lymphoma is the most common lymphoma, generally responsible for between 25-30% cases of Non-Hodgkin lymphoma. In nodal or extranodal locations, it often manifests as rapidly expanding lymph nodes. They react effectively to six rounds of rituximab in conjunction with cyclophosphamide, doxorubicin, vincristine, and prednisone, despite their aggressive nature.
B lymphocytes, T lymphocytes, and natural killer cells (NK) may produce lymphoma, a cancer of the lymphoid system. It can be categorized as Hodgkin or Non-Hodgkin lymphoma. Approximately 80 percent of all lymphomas are NHL.
B-cells are known to possess functional variety and the ability to convert into numerous different pathways. Because of DLBCl’s functional diversity, it constitutes a collection of clinically and pathologically diverse illnesses. More than 30 subtypes of NHL have been found, with follicular lymphoma and DLBCL being the most frequent.
Epidemiology
In the United States, the incidence of NHL isn’t very prevalent, at around 7 cases per 100,000 annually. Diffuse large B cell lymphoma accounts for around 25% of all Non-Hogkin lymphoma cases globally.
FL is the second most common NHL, following DLBCL. The disease is most prevalent among white-skinned individuals, followed by African Americans and Asians, with a concentration of males and a median age of 64.
Anatomy
Pathophysiology
The majority of patients with diffuse large B-cell lymphoma exhibit gene rearrangements in the immunoglobulin heavy and light chains. Approximately 80% of patients with Diffuse Large B-cell Lymphoma express the BCL2 protein, whereas 70% of patients express the B cell lymphoma 6 (BCL6) protein.
Some of them also exhibit MYC gene abnormalities. Flow cytometry indicates the presence of CD79a, CD45, CD22, CD20, and CD19. CD30 is present in 25% of patients and is indicative of a favorable outcome. Most DLBCL patients rarely exhibit CD5, which is associated with a bad prognosis.
Technologies such as gene expression profiling (GEP) can categorize DLBCL into germinal center B-cells (GCB) and activated B-cells to better understand the molecular diversity among visually comparable variations of Diffuse large B cell. Over fifty percent of DLBCL express cytoplasmic or surface IgM immunoglobulin.
Double hit lymphoma resembles DLBCL but contains MYC in addition to BCL2 and/or BCL6. A triple hit lymphoma is characterized by alterations in MYC, BCL6, and BCL2 genes. t(14;18) is associated with diffuse and nodal illness, although it does not predict a bad prognosis. The t(14:18) is observed in about 90% of follicular lymphoma patients and approximately 30% of patients with DLBCL.
This condition frequently affects extranodal locations, such as the bones, kidneys, adrenal glands, certain soft tissues and the brain. Pathophysiological mechanisms of NHL B cell lymphomas are dependent on lymphoma subtype. Based on when the malignancy is detached in B cells, B cell lymphomas can be categorized.
Due to an expansion of B lymphocytes within or near the germinal center, lymphadenopathy occurs. B-symptoms are brought on by an increase in cytokine production. High levels of uric acid and LDH indicate a rapid rate of cell turnover and systemic release of breakdown products.
Etiology
B cell lymphomas are caused by the malignant expansion of B cells at various phases of their development. A cell of origin (COO) is hypothesized based on the morphology, genetics, and immunophenotype of the neoplastic cells.
There are three stages in the development of B cells:
Pre-germinal
Germinal
Post-germinal
B cell lymphomas, like any other malignancy, can originate from genetic abnormalities affecting proto-oncogenes and tumor suppressor genes; however, the lymph node environment can also promote lymphomagenesis. The majority of B-cell lymphomas originate from the germinal center.
20-40% of patients exhibit genetic abnormalities in the BCL6 gene. Patients with HIV might have a high incidence of Non-Hodgkin Lymphoma due to a chronic immunodeficiency of B and T cell stimulation. As observed in Burkitt’s lymphoma, some infectious agents are capable of manipulating DNA.
In Burkitt’s Lymphoma, the Epstein Barr virus DNA is carried into the B cell nucleus, hence affecting B cell growth and development. HIV is a risk factor for the formation of tumors because it impairs the host’s capacity to control malignant cells.
Similarly, immunosuppressive medication administered to transplant patients increase the risk for patients to develop B-cell lymphomas. Diffuse Large B-cell lymphoma can also occur from the Retches transformation of some other lymphomas such as:
Chronic lymphocytes leukemia
Marginal zone lymphoma
Splenic Marginal zone lymphoma
Additional factors which increase the risk of developing B-cell lymphomas are:
History of radiation
Chemotherapy
Personal/family history of lymphoma
In addition to dyes and pesticides, chemical substances can raise the risk of lymphoma. Non-Hodgkin lymphoma is more prevalent in obese patients and those with an autoimmune illness background.
Genetics
Prognostic Factors
As established by the international prognostic index, 5 factors determine the survival rate of Diffuse large B-cell lymphoma:
Age above 60 years
High LDH levels
Eastern Cooperative Oncology group performance above or equal to 2
Ann Arbor stage III/IV
Number of extranodal sites equal to or greater than 2
Survival rates for patients with 0-3 of these risk factors ranged between 32%-83%, and there was a 15% increase in survival when rituximab was prescribed in addition to conventional CHOP chemotherapy.
DLBCL is an aggressive illness that can be treated in up to 50% of patients who achieve complete remission after receiving first-line therapy. The GCB cell type has a more favorable prognosis than the ABC cell type. Compared to DLBCL, double and triple hit lymphomas have a worse prognosis.
Cycles 1 and 2: 0.15 mg/kg intravenous every 3Weeks
Cycle 3 and afterwards: 0.075 mg/kg intravenous every 3Weeks
Dose Adjustments
Dosage Modifications
Reduce following doses by 50% if administration is delayed for more than 3 weeks due to the toxicity; if the toxicity returns despite the dose decrease, consider stopping the medication
Reduce the dosage to 0.075 mg/kg for Cycle 3 if toxicity requires it after the second dosage of 0.15 mg/kg (Cycle 2) Haematological adverse effects
Neutropenia (ANC below 1x 109/L): Withhold till ANC is above 1 x 109/L
Thrombocytopenia (platelets below 50,000/mcL): Withhold till platelets above 50,000/mcL Nonhematological adverse effects
Effusion or Edema Grade above 2: Withhold till it gets resolved to Grade below 1
Other adverse effects Grade above 3: Withhold till it gets resolved to Grade below 1 Hepatic impairment<
Mild: dose adjustment is not necessary; monitor individuals with mild liver impairment for increased risk of adverse effects and adjust the dose as required
Moderate or severe: Not well known. Renal impairment
excreted Minimally by the kidneys
Mild/moderate (CrCl 30 to below 90 mL/min): There were no clinically significant pharmacokinetic changes.
Severe (CrCl 15 to 29 mL/min) ESRD with/without hemodialysis: unknown Pharmacokinetics
Lymphodepleting chemotherapy
Lymphodepleting chemotherapy may be omitted if white blood cells count less than or equal to 1 x 109/L within 1 week before tisagenlecleucel infusion
3 days of daily intravenous administration of 25 mg/m2 fludarabine
commencing with the first dosage of fludarabine, 250 mg/m2 of cyclophosphamide is administered intravenously every day for 3 days
tisagenlecleucel intravenous infusion
Administer 2 to 6 days after completing lymphodepleting chemotherapy
Indicated for treating diffuse large B-cell lymphoma (DLBCL), doxorubicin, cyclophosphamide, and prednisone (R-CHP) are recommended in addition to a rituximab product.
For a total of six cycles, administer every 21-day cycle.
Day 1:
Administer 10mg prednisolone orally, then,
Administer 1.8mg/kg Intravenous plus of polatuzumab vedotin
Administer 750 mg/m2 of cyclophosphamide Intravenous PLUS
Administer 50 mg/m2 of doxorubicin Intravenous PLUS
Administer 375 mg/m2 of rituximab product Intravenous PLUS
Following the Day 1 dosage of prednisone, medicines may be given in any order.
Day 2 to 5:
Administer 100mg orally every day.
Relapsed or refractory
Indicated for use with rituximab and a bendamustine product in treating people with diffuse large B-cell lymphoma (DLBCL) who have experienced recurrence or refractory disease after at least more than two previous therapies.
For a total of six cycles, administer every 21-day cycle.
Day 1:
Administer 1.8mg/kg Intravenous plus of polatuzumab vedotin
Administer 375 mg/m2 of rituximab product Intravenous PLUS
Administer 90 mg/m² of bendamustine Intravenously
Can administer the doses in any sequence
Day 2:
Administer 90 mg/m² of bendamustine Intravenously
Diffuse large B cell lymphoma is the most common lymphoma, generally responsible for between 25-30% cases of Non-Hodgkin lymphoma. In nodal or extranodal locations, it often manifests as rapidly expanding lymph nodes. They react effectively to six rounds of rituximab in conjunction with cyclophosphamide, doxorubicin, vincristine, and prednisone, despite their aggressive nature.
B lymphocytes, T lymphocytes, and natural killer cells (NK) may produce lymphoma, a cancer of the lymphoid system. It can be categorized as Hodgkin or Non-Hodgkin lymphoma. Approximately 80 percent of all lymphomas are NHL.
B-cells are known to possess functional variety and the ability to convert into numerous different pathways. Because of DLBCl’s functional diversity, it constitutes a collection of clinically and pathologically diverse illnesses. More than 30 subtypes of NHL have been found, with follicular lymphoma and DLBCL being the most frequent.
In the United States, the incidence of NHL isn’t very prevalent, at around 7 cases per 100,000 annually. Diffuse large B cell lymphoma accounts for around 25% of all Non-Hogkin lymphoma cases globally.
FL is the second most common NHL, following DLBCL. The disease is most prevalent among white-skinned individuals, followed by African Americans and Asians, with a concentration of males and a median age of 64.
The majority of patients with diffuse large B-cell lymphoma exhibit gene rearrangements in the immunoglobulin heavy and light chains. Approximately 80% of patients with Diffuse Large B-cell Lymphoma express the BCL2 protein, whereas 70% of patients express the B cell lymphoma 6 (BCL6) protein.
Some of them also exhibit MYC gene abnormalities. Flow cytometry indicates the presence of CD79a, CD45, CD22, CD20, and CD19. CD30 is present in 25% of patients and is indicative of a favorable outcome. Most DLBCL patients rarely exhibit CD5, which is associated with a bad prognosis.
Technologies such as gene expression profiling (GEP) can categorize DLBCL into germinal center B-cells (GCB) and activated B-cells to better understand the molecular diversity among visually comparable variations of Diffuse large B cell. Over fifty percent of DLBCL express cytoplasmic or surface IgM immunoglobulin.
Double hit lymphoma resembles DLBCL but contains MYC in addition to BCL2 and/or BCL6. A triple hit lymphoma is characterized by alterations in MYC, BCL6, and BCL2 genes. t(14;18) is associated with diffuse and nodal illness, although it does not predict a bad prognosis. The t(14:18) is observed in about 90% of follicular lymphoma patients and approximately 30% of patients with DLBCL.
This condition frequently affects extranodal locations, such as the bones, kidneys, adrenal glands, certain soft tissues and the brain. Pathophysiological mechanisms of NHL B cell lymphomas are dependent on lymphoma subtype. Based on when the malignancy is detached in B cells, B cell lymphomas can be categorized.
Due to an expansion of B lymphocytes within or near the germinal center, lymphadenopathy occurs. B-symptoms are brought on by an increase in cytokine production. High levels of uric acid and LDH indicate a rapid rate of cell turnover and systemic release of breakdown products.
B cell lymphomas are caused by the malignant expansion of B cells at various phases of their development. A cell of origin (COO) is hypothesized based on the morphology, genetics, and immunophenotype of the neoplastic cells.
There are three stages in the development of B cells:
Pre-germinal
Germinal
Post-germinal
B cell lymphomas, like any other malignancy, can originate from genetic abnormalities affecting proto-oncogenes and tumor suppressor genes; however, the lymph node environment can also promote lymphomagenesis. The majority of B-cell lymphomas originate from the germinal center.
20-40% of patients exhibit genetic abnormalities in the BCL6 gene. Patients with HIV might have a high incidence of Non-Hodgkin Lymphoma due to a chronic immunodeficiency of B and T cell stimulation. As observed in Burkitt’s lymphoma, some infectious agents are capable of manipulating DNA.
In Burkitt’s Lymphoma, the Epstein Barr virus DNA is carried into the B cell nucleus, hence affecting B cell growth and development. HIV is a risk factor for the formation of tumors because it impairs the host’s capacity to control malignant cells.
Similarly, immunosuppressive medication administered to transplant patients increase the risk for patients to develop B-cell lymphomas. Diffuse Large B-cell lymphoma can also occur from the Retches transformation of some other lymphomas such as:
Chronic lymphocytes leukemia
Marginal zone lymphoma
Splenic Marginal zone lymphoma
Additional factors which increase the risk of developing B-cell lymphomas are:
History of radiation
Chemotherapy
Personal/family history of lymphoma
In addition to dyes and pesticides, chemical substances can raise the risk of lymphoma. Non-Hodgkin lymphoma is more prevalent in obese patients and those with an autoimmune illness background.
As established by the international prognostic index, 5 factors determine the survival rate of Diffuse large B-cell lymphoma:
Age above 60 years
High LDH levels
Eastern Cooperative Oncology group performance above or equal to 2
Ann Arbor stage III/IV
Number of extranodal sites equal to or greater than 2
Survival rates for patients with 0-3 of these risk factors ranged between 32%-83%, and there was a 15% increase in survival when rituximab was prescribed in addition to conventional CHOP chemotherapy.
DLBCL is an aggressive illness that can be treated in up to 50% of patients who achieve complete remission after receiving first-line therapy. The GCB cell type has a more favorable prognosis than the ABC cell type. Compared to DLBCL, double and triple hit lymphomas have a worse prognosis.
Cycles 1 and 2: 0.15 mg/kg intravenous every 3Weeks
Cycle 3 and afterwards: 0.075 mg/kg intravenous every 3Weeks
Dose Adjustments
Dosage Modifications
Reduce following doses by 50% if administration is delayed for more than 3 weeks due to the toxicity; if the toxicity returns despite the dose decrease, consider stopping the medication
Reduce the dosage to 0.075 mg/kg for Cycle 3 if toxicity requires it after the second dosage of 0.15 mg/kg (Cycle 2) Haematological adverse effects
Neutropenia (ANC below 1x 109/L): Withhold till ANC is above 1 x 109/L
Thrombocytopenia (platelets below 50,000/mcL): Withhold till platelets above 50,000/mcL Nonhematological adverse effects
Effusion or Edema Grade above 2: Withhold till it gets resolved to Grade below 1
Other adverse effects Grade above 3: Withhold till it gets resolved to Grade below 1 Hepatic impairment<
Mild: dose adjustment is not necessary; monitor individuals with mild liver impairment for increased risk of adverse effects and adjust the dose as required
Moderate or severe: Not well known. Renal impairment
excreted Minimally by the kidneys
Mild/moderate (CrCl 30 to below 90 mL/min): There were no clinically significant pharmacokinetic changes.
Severe (CrCl 15 to 29 mL/min) ESRD with/without hemodialysis: unknown Pharmacokinetics
Lymphodepleting chemotherapy
Lymphodepleting chemotherapy may be omitted if white blood cells count less than or equal to 1 x 109/L within 1 week before tisagenlecleucel infusion
3 days of daily intravenous administration of 25 mg/m2 fludarabine
commencing with the first dosage of fludarabine, 250 mg/m2 of cyclophosphamide is administered intravenously every day for 3 days
tisagenlecleucel intravenous infusion
Administer 2 to 6 days after completing lymphodepleting chemotherapy
Indicated for treating diffuse large B-cell lymphoma (DLBCL), doxorubicin, cyclophosphamide, and prednisone (R-CHP) are recommended in addition to a rituximab product.
For a total of six cycles, administer every 21-day cycle.
Day 1:
Administer 10mg prednisolone orally, then,
Administer 1.8mg/kg Intravenous plus of polatuzumab vedotin
Administer 750 mg/m2 of cyclophosphamide Intravenous PLUS
Administer 50 mg/m2 of doxorubicin Intravenous PLUS
Administer 375 mg/m2 of rituximab product Intravenous PLUS
Following the Day 1 dosage of prednisone, medicines may be given in any order.
Day 2 to 5:
Administer 100mg orally every day.
Relapsed or refractory
Indicated for use with rituximab and a bendamustine product in treating people with diffuse large B-cell lymphoma (DLBCL) who have experienced recurrence or refractory disease after at least more than two previous therapies.
For a total of six cycles, administer every 21-day cycle.
Day 1:
Administer 1.8mg/kg Intravenous plus of polatuzumab vedotin
Administer 375 mg/m2 of rituximab product Intravenous PLUS
Administer 90 mg/m² of bendamustine Intravenously
Can administer the doses in any sequence
Day 2:
Administer 90 mg/m² of bendamustine Intravenously
Diffuse large B cell lymphoma is the most common lymphoma, generally responsible for between 25-30% cases of Non-Hodgkin lymphoma. In nodal or extranodal locations, it often manifests as rapidly expanding lymph nodes. They react effectively to six rounds of rituximab in conjunction with cyclophosphamide, doxorubicin, vincristine, and prednisone, despite their aggressive nature.
B lymphocytes, T lymphocytes, and natural killer cells (NK) may produce lymphoma, a cancer of the lymphoid system. It can be categorized as Hodgkin or Non-Hodgkin lymphoma. Approximately 80 percent of all lymphomas are NHL.
B-cells are known to possess functional variety and the ability to convert into numerous different pathways. Because of DLBCl’s functional diversity, it constitutes a collection of clinically and pathologically diverse illnesses. More than 30 subtypes of NHL have been found, with follicular lymphoma and DLBCL being the most frequent.
In the United States, the incidence of NHL isn’t very prevalent, at around 7 cases per 100,000 annually. Diffuse large B cell lymphoma accounts for around 25% of all Non-Hogkin lymphoma cases globally.
FL is the second most common NHL, following DLBCL. The disease is most prevalent among white-skinned individuals, followed by African Americans and Asians, with a concentration of males and a median age of 64.
The majority of patients with diffuse large B-cell lymphoma exhibit gene rearrangements in the immunoglobulin heavy and light chains. Approximately 80% of patients with Diffuse Large B-cell Lymphoma express the BCL2 protein, whereas 70% of patients express the B cell lymphoma 6 (BCL6) protein.
Some of them also exhibit MYC gene abnormalities. Flow cytometry indicates the presence of CD79a, CD45, CD22, CD20, and CD19. CD30 is present in 25% of patients and is indicative of a favorable outcome. Most DLBCL patients rarely exhibit CD5, which is associated with a bad prognosis.
Technologies such as gene expression profiling (GEP) can categorize DLBCL into germinal center B-cells (GCB) and activated B-cells to better understand the molecular diversity among visually comparable variations of Diffuse large B cell. Over fifty percent of DLBCL express cytoplasmic or surface IgM immunoglobulin.
Double hit lymphoma resembles DLBCL but contains MYC in addition to BCL2 and/or BCL6. A triple hit lymphoma is characterized by alterations in MYC, BCL6, and BCL2 genes. t(14;18) is associated with diffuse and nodal illness, although it does not predict a bad prognosis. The t(14:18) is observed in about 90% of follicular lymphoma patients and approximately 30% of patients with DLBCL.
This condition frequently affects extranodal locations, such as the bones, kidneys, adrenal glands, certain soft tissues and the brain. Pathophysiological mechanisms of NHL B cell lymphomas are dependent on lymphoma subtype. Based on when the malignancy is detached in B cells, B cell lymphomas can be categorized.
Due to an expansion of B lymphocytes within or near the germinal center, lymphadenopathy occurs. B-symptoms are brought on by an increase in cytokine production. High levels of uric acid and LDH indicate a rapid rate of cell turnover and systemic release of breakdown products.
B cell lymphomas are caused by the malignant expansion of B cells at various phases of their development. A cell of origin (COO) is hypothesized based on the morphology, genetics, and immunophenotype of the neoplastic cells.
There are three stages in the development of B cells:
Pre-germinal
Germinal
Post-germinal
B cell lymphomas, like any other malignancy, can originate from genetic abnormalities affecting proto-oncogenes and tumor suppressor genes; however, the lymph node environment can also promote lymphomagenesis. The majority of B-cell lymphomas originate from the germinal center.
20-40% of patients exhibit genetic abnormalities in the BCL6 gene. Patients with HIV might have a high incidence of Non-Hodgkin Lymphoma due to a chronic immunodeficiency of B and T cell stimulation. As observed in Burkitt’s lymphoma, some infectious agents are capable of manipulating DNA.
In Burkitt’s Lymphoma, the Epstein Barr virus DNA is carried into the B cell nucleus, hence affecting B cell growth and development. HIV is a risk factor for the formation of tumors because it impairs the host’s capacity to control malignant cells.
Similarly, immunosuppressive medication administered to transplant patients increase the risk for patients to develop B-cell lymphomas. Diffuse Large B-cell lymphoma can also occur from the Retches transformation of some other lymphomas such as:
Chronic lymphocytes leukemia
Marginal zone lymphoma
Splenic Marginal zone lymphoma
Additional factors which increase the risk of developing B-cell lymphomas are:
History of radiation
Chemotherapy
Personal/family history of lymphoma
In addition to dyes and pesticides, chemical substances can raise the risk of lymphoma. Non-Hodgkin lymphoma is more prevalent in obese patients and those with an autoimmune illness background.
As established by the international prognostic index, 5 factors determine the survival rate of Diffuse large B-cell lymphoma:
Age above 60 years
High LDH levels
Eastern Cooperative Oncology group performance above or equal to 2
Ann Arbor stage III/IV
Number of extranodal sites equal to or greater than 2
Survival rates for patients with 0-3 of these risk factors ranged between 32%-83%, and there was a 15% increase in survival when rituximab was prescribed in addition to conventional CHOP chemotherapy.
DLBCL is an aggressive illness that can be treated in up to 50% of patients who achieve complete remission after receiving first-line therapy. The GCB cell type has a more favorable prognosis than the ABC cell type. Compared to DLBCL, double and triple hit lymphomas have a worse prognosis.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
